Background {#Sec1}
==========

Chronic pain is a major public health challenge owing, in part, to its prevalence and economic burden \[[@CR1]\]. In 2012, approximately 25 million Americans were living with chronic pain, which resulted in reduced health-related quality of life (HRQL) and work productivity \[[@CR2], [@CR3]\]. The economic impact of chronic pain has been estimated to be \$560--635 billion per year in 2010 US dollars \[[@CR1]\].

The long-term management of chronic pain with opioids should only be initiated when other pain treatments, such as non-opioid pain medicines or immediate-release opioid medicines, are ineffective or are not tolerated \[[@CR4], [@CR5]\]. Guidelines developed by the American Pain Society, the American Academy of Pain Medicine, and the Centers for Disease Control and Prevention stress the importance of patient assessment and monitoring to avoid opioid misuse or abuse \[[@CR5], [@CR6]\]. Despite these measures, opioid abuse is a recognized problem that is approaching epidemic proportions \[[@CR7]\].

Abuse-deterrent opioids (ADOs) have been developed as part of a multifaceted approach to enable safer use of opioids \[[@CR8]\]. ADOs include formulations that impede tampering by physical (e.g., crush-resistant) or chemical (e.g., opioid receptor antagonist) means \[[@CR8]\]. Designed as an ADO, ALO-02 capsules comprise pellets of extended-release oxycodone hydrochloride and sequestered naltrexone hydrochloride, an opioid receptor antagonist.

The efficacy and safety results of a phase III clinical trial to evaluate the analgesic efficacy of ALO-02, when compared with placebo, in patients with moderate-to-severe chronic low back pain (CLBP) have been published \[[@CR9]\]. This study showed that treatment with ALO-02 was superior to placebo for low back pain as measured on the 11-point Numeric Rating Scale (NRS)-Pain. Similar results were also seen on the Brief Pain Inventory-Short Form (BPI-sf). Patients treated with ALO-02 reported improvement during the open-label titration period on other assessments such as the Patient's Global Assessment (PGA) of Low Back Pain and Roland Morris Disability Questionnaire (RMDQ). Satisfaction with Treatment favored ALO-02 over placebo. Overall, this study found that ALO-02 was efficacious in treating CLBP and presented a safety profile similar to that of other opioids \[[@CR9]\].

The current paper focuses on secondary objectives of this study that relate to additional patient-reported outcomes of ALO-02 in treating CLBP. Assessments of HRQL, work productivity, and activity impairment in patients treated with ALO-02 for the management of moderate-to-severe CLBP are reported here.

Methods {#Sec2}
=======

This was a double-blind, placebo-controlled, randomized withdrawal study in patients from the United States with moderate-to-severe CLBP (ClinicalTrials.gov: NCT01571362). Informed consent and institutional review board approval were obtained before study initiation.

Study population {#Sec3}
----------------

Patients (aged ≥18 years) with a documented diagnosis of nonspecific moderate-to-severe CLBP present for at least three months requiring continuous around-the-clock opioid analgesic treatment and an average daily NRS-Pain score for low back pain of ≥5 and ≤9 were included in the study. Major exclusion criteria were history (within the past 2 years) of lumbosacral radiculopathy, spinal stenosis, documented drug or alcohol abuse, or a positive urine drug test for illicit substances or opioid medications not prescribed to the patient.

Study design {#Sec4}
------------

This study consisted of four periods, starting with an initial screening period lasting ≤2 weeks during which standard medical assessments were conducted to determine patient eligibility. Eligible patients entered an open-label ALO-02 conversion titration period (4--6 weeks) during which pain management was individualized by titrating ALO-02. At the end of the open-label titration period, patients tolerating ALO-02 and with NRS-Pain scores of 4 or lower were then randomized to either continue on active ALO-02 treatment or placebo. Patients were randomized in a 1:1 ratio using an interactive voice or web response system to receive a randomization number and blinded treatment assignment. Randomization was stratified by prior pain analgesic (opioid or non-opioid) and study center. Patients, investigators and clinic personnel were blinded to the randomized drug. The double-blind randomization period included a two-week blinded taper for both the treatment and placebo arms to ensure integrity of blinded data, followed by 10 weeks of treatment with ALO-02 or placebo. During the two-week post-treatment follow-up period, patients were tapered off ALO-02 and converted to standard of care treatment.

Patient-reported outcome assessments {#Sec5}
------------------------------------

HRQL was measured using the Short Form-36v2 Health Survey (SF-36v2) \[[@CR10]\] and the EuroQol-5 Dimensions Health Questionnaire 3-Level version (EQ-5D-3L) \[[@CR11], [@CR12]\].

The SF-36v2 is a self-administered questionnaire measuring physical functioning, role limitations due to physical problems, social functioning, bodily pain, mental health, role limitations due to emotional problems, vitality, and general health perception. These eight domains also combine to form two component summary scores, the Physical Component Summary and the Mental Component Summary. Scores range from 0 to 100, with higher scores indicating better health states.

The EQ-5D-3L is a self-completed standardized instrument used as a generic measure of health status using a simple descriptive profile consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which is assessed on a three-level severity scale (no problems, some or moderate problems, extreme problems). These scores are combined to form a single index utility value with higher scores indicating better health. Additionally, a standard vertical 20 cm visual analog scale (VAS) was used to record an individual's rating of their current health status.

Work productivity and activity impairment were measured using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) \[[@CR13]\]. The WPAI:SHP questionnaire measured the effect of a specific health problem (i.e. low back pain) on work productivity and activity impairment. Specific outcomes were absenteeism (work time missed), presenteeism (impairment while working), overall work impairment (absenteeism plus presenteeism), and activity impairment (impairment in regular activities) due to CLBP. Each score is represented as a percentage, with higher scores indicating less productivity or greater impairment.

Endpoints {#Sec6}
---------

The endpoints assessed were mean changes in the SF-36v2, EQ-5D-3L, and the WPAI:SHP from screening period to the end of titration period (open-label titration period), from randomization baseline to the end of study (double-blind treatment period), and from screening period to the end of double-blind treatment period (overall study period).

Statistical analyses {#Sec7}
--------------------

Analysis of patient-reported outcomes was conducted on all patients during the titration period and on the intent-to-treat (ITT) population, consisting of all randomized patients who received at least one dose of study medication after randomization. For changes during the open-label titration period, a paired *t* test was used on observed data. For changes during the double-blind treatment period and overall study period, analysis of covariance was used, with treatment and prior pain analgesic (opioid or non-opioid) as categorical factors and the screening or baseline score and final total daily dose of the titration period (for double-blind treatment period analysis only) as covariates. Last observation carried forward was used for missing data at the end of the treatment or study period.

Results {#Sec8}
=======

Patients {#Sec9}
--------

Of the 410 patients who received ALO-02 during the open-label titration period, 280 (ITT population) were treated during the double-blind treatment period (placebo, *n* = 134; ALO-02, *n* = 146). Detailed demographic data from this study have been published \[[@CR9]\]. During the open-label titration period, 56.8% of patients were female, and patients had a mean (SD) age of 50.1 (12.48) years and a mean (SD) body mass index of 30.2 (5.46) kg/m^2^. Of the patients randomized to the double-blind treatment period, 57.5% were non-opioid users prior to the start of this study. These patients reported a mean NRS-Pain score of 7.1 and a mean BPI-sf score of 6.7 at screening. Overall, patient demographics were similar between the placebo and ALO-02 groups. The most common reasons for patients not entering the double-blind treatment period were AEs (13.9%) and "did not meet entrance criteria" (10.0%), which included those unable to tolerate ALO-02 and not meeting treatment response criteria for randomization.

Patient-reported outcomes {#Sec10}
-------------------------

During the open-label titration period, changes on the SF-36v2 showed statistically significant improvement for all subscales for all patients (*p* ≤ 0.0026) and ITT patients (*p* \< 0.0001; Table [1](#Tab1){ref-type="table"}). Statistically significant improvement was also observed for the EQ-5D-3L summary index and VAS for all patients and ITT patients (*p* \< 0.0001 for both populations). Improvement was also statistically significant for all patients (*p* \< 0.0001) and the ITT population (*p* ≤ 0.0017) for all WPAI:SHP outcomes, except the work time missed due to low back pain subscale for all patients (*p* = 0.3822).Table 1Change in patient-reported outcomes -- titration periodInstrumentAll patientsITT patientsMean change*p*-valueMean change*p*-valueShort Form-36v2 Health Survey^a^ Physical Functioning6.7\<0.00018.0\<0.0001 Role-Physical7.7\<0.00019.1\<0.0001 Bodily Pain9.8\<0.000111.6\<0.0001 General Health2.3\<0.00013.1\<0.0001 Vitality4.6\<0.00015.8\<0.0001 Social Functioning5.0\<0.00017.0\<0.0001 Role-Emotional3.4\<0.00014.7\<0.0001 Mental Health2.3\<0.00013.5\<0.0001 Physical Component Score8.2\<0.00019.6\<0.0001 Mental Component Score1.60.00262.9\<0.0001EuroQol-5 Dimensions 3-Level^b^ Summary Index0.12\<0.00010.14\<0.0001 Visual Analog Scale8.16\<0.00019.84\<0.0001Work Productivity and Activity Impairment Questionnaire: Specific Health Problem^c^ Percentage work time missed due to low back pain−1.30.3822−4.90.0017 Percentage impairment while working due to low back pain−22.4\<0.0001−25.9\<0.0001 Percentage overall work impairment due to low back pain−21.6\<0.0001−26.9\<0.0001 Percentage activity impairment due to low back pain−27.2\<0.0001−32.0\<0.0001*ITT* intent to treat^a^Higher scores indicate a better health-related quality of life. ^b^Higher scores indicate a better health. ^c^Higher scores indicate less productivity/greater impairment

During the double-blind treatment period, the difference between patients randomized to placebo and patients randomized to continue ALO-02 for the mean change in SF-36v2 was statistically significant only for the bodily pain subscale (*p* = 0.0100; Table [2](#Tab2){ref-type="table"}). No statistically significant treatment differences were observed for changes in the EQ-5D-3L summary index and VAS, or the WPAI:SHP.Table 2Change in patient-reported outcomes -- double-blind treatment periodInstrumentLS Mean ChangePlaceboALO-02Difference^a^*p*-valueShort Form-36v2 Health Survey Physical Functioning−2.06−1.440.620.5181 Role-Physical−2.56−2.59−0.030.9733 Bodily Pain−5.07−2.692.370.0100 General Health−1.55−2.10−0.550.4712 Vitality−1.62−2.77−1.160.2898 Social Functioning−3.17−1.691.480.1565 Role-Emotional−2.57−3.44−0.860.5220 Mental Health−2.95−2.930.020.9865 Physical Component Score−2.70−1.681.020.2491 Mental Component Score−2.29−2.98−0.690.5219EuroQol 5-Dimensions 3-Level Summary Index−0.061−0.0290.0320.0605 Visual Analog Scale−3.61−2.890.720.7196Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Percentage work time missed due to low back pain6.493.72−2.770.4944 Percentage impairment while working due to low back pain6.774.39−2.380.6008 Percentage overall work impairment due to low back pain10.855.71−5.140.3604 Percentage activity impairment due to low back pain10.566.41−4.150.1031*ALO-02* extended-release oxycodone and sequestered naltrexone, *LS* least squares^a^Difference calculated as ALO-02 minus placebo; a positive difference favors ALO-02, and a negative difference favors placebo for SF-36v2 and EQ-5D-3L; a negative difference favors ALO-02 for WPAI:SHP

For the overall study period, the difference between patients randomized to placebo and patients randomized to continue ALO-02 for the mean change in SF-36v2 was statistically significant only for the bodily pain subscale (*p* = 0.0232; Table [3](#Tab3){ref-type="table"}). There were no statistically significant differences between placebo and ALO-02 in either the EQ-5D-3L summary index or VAS. The WPAI:SHP showed a statistically significant difference only for mean change in percentage of activity impairment due to low back pain (*p* = 0.0040) for patients treated with ALO-02 compared with those on placebo.Table 3Change in patient-reported outcomes -- overall study periodInstrumentLS Mean ChangePlaceboALO-02Difference^a^*p*-valueShort Form-36v2 Health Survey Physical Functioning5.326.841.520.1731 Role-Physical5.686.781.100.3290 Bodily Pain6.398.782.390.0232 General Health1.281.07−0.200.8139 Vitality3.463.01−0.450.6878 Social Functioning3.585.572.000.0658 Role-Emotional0.991.220.230.8670 Mental Health0.090.470.370.7259 Physical Component Score6.428.091.670.0989 Mental Component Score−0.44−0.450.000.9969EuroQol 5-Dimensions-3 Level Summary Index0.0850.1060.0210.2280 Visual Analog Scale4.757.012.260.2701Work Productivity and Activity Impairment Questionnaire: Specific Health Problem Percentage work time missed due to low back pain−1.00−2.09−1.090.7480 Percentage impairment while working due to low back pain−16.18−25.38−9.200.0581 Percentage overall work impairment due to low back pain−15.16−25.51−10.350.0679 Percentage activity impairment due to low back pain−18.62−26.81−8.190.0040*ALO-02* extended-release oxycodone and sequestered naltrexone, *LS* least squares^a^Difference calculated as ALO-02 minus placebo; a positive difference favors ALO-02 and a negative difference favors placebo for SF-36v2 and EQ-5D-3L; a negative difference favors ALO-02 for WPAI:SHP

Discussion {#Sec11}
==========

Patient-reported outcomes are useful in evaluating treatment efficacy and interpreting clinical outcomes \[[@CR14]\]. This study assessed these outcomes in a chronic pain population enriched by treatment responders. A randomized withdrawal trial design is recommended by the FDA to reduce placebo exposure and minimize high dropout rates associated with clinical trials of opioids. This design may be especially suitable to test reformulations of approved opioids \[[@CR15]\]. The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) guidelines suggest this trial design may increase assay sensitivity \[[@CR16]\]. The results of the open-label titration period may provide valuable insights since it is thought to closely mimic clinical practice \[[@CR17]\].

The primary efficacy and safety data from this study showed that ALO-02 was superior to placebo in reducing pain in patients with CLBP and exhibited a safety profile similar to that of other opioids \[[@CR9]\]. In the current analysis, patients reported significant improvement in HRQL, work productivity, and activity impairment with ALO-02 during the open-label titration period, which parallels the significant pain reduction associated with CLBP observed after ALO-02 administration during this period \[[@CR9]\]. The change in the EQ-5D summary index from screening to the end of the open-label titration period of 0.14 is above a previously reported mean minimal important difference of 0.074 (range, −0.011--0.140), indicating a clinically relevant change in health status \[[@CR18]\]. This minimal important difference for the EQ-5D summary index was determined using studies in different patient populations, including those with back pain \[[@CR18]\]. The change in the physical component score of 8.2--9.6 derived using the SF-36v2 questionnaire during the open-label titration period was also above the 1.26--5.95 range for clinical relevance reported previously in patients recovering from lumbar spine surgery \[[@CR19]\].

The bodily pain subscale of the SF-36v2 significantly favored patients randomized to continue ALO-02 compared with patients randomized to placebo during the double-blind treatment period, but other measures of HRQL, work productivity, and activity impairment did not show significant differences. This may be due to effects of ALO-02 persisting from the open-label period in patients randomized to placebo for the double-blind period. The specific design of randomized withdrawal trials, where the outcome of the double-blind treatment period is assessed on the worsening of pain with placebo relative to the active arm, may also contribute to the lack of significant differences between placebo and ALO-02 treatments \[[@CR17]\].

When considering the overall study period, the bodily pain subscale of the SF-36v2 showed a significant difference. This is supported by the significant difference between ALO-02 and placebo in the WPAI:SHP measure of activity impairment due to low back pain during the overall study period.

There are limitations of this study that should be taken into consideration. First, the results may not be generalizable to a wider population because the placebo-controlled double-blind treatment period included a population enriched with treatment responders, whereas the open-label period of the study, which included all eligible patients, was uncontrolled. Second, improvements on various patient-reported outcome measures in the open-label titration period were based on comparison to baseline only, as this portion of the study by design was not placebo-controlled. Finally, the study was powered for the primary efficacy endpoint of NRS-Pain and not these secondary outcome measures.

Conclusion {#Sec12}
==========

ALO-02 may improve HRQL, work productivity, and activity impairment in patients with chronic low back pain. Improvement was generally maintained during the randomized double-blind treatment period, although few treatment differences were observed. ALO-02 appears effective for pain relief and potentially also functional improvement in this chronic pain population. Further studies are needed to evaluate patient-reported functional outcomes as a primary or secondary endpoint in chronic pain populations.
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